September 3rd, 2010 | Bhopal
Cipla, the leading pharmaceutical company today announced the launch of Progress to Prosper (P2P), a revolutionary asthma training and support initiative for the primary healthcare doctors across Madhya Pradesh. Developed in association with Surya Chest Foundation, Lucknow, P2P has already been hugely successful in enhancing asthma care in Uttar Pradesh, Rajasthan and Haryana. The first workshop in the region will be extended to over 475 primary healthcare doctors in across cities like Bhopal, Jabalpur, Katni, Gwalior, Sagar, Indore, Ujjain and Khandwa. P2P is the first and only program in India on diagnosis and management of asthma and with the support of doctors trained under P2P in the past 2 years, the best asthma treatment is now a reality even in small town India.
With over 30 million asthmatics in the country, India constitutes 10% of the world asthmatics which indicates that the asthma population in India is larger than the entire population of several countries. The scenario is worse as most in India are either unaware, undiagnosed or are sub-optimally treated for asthma. This is despite India having the latest, most effective and extremely affordable medicines to control asthma. In order to bridge this diagnosis-treatment gap and spread awareness, a holistic approach has been adopted in which P2P is proved to be the most important link.
Addressing the press, Dr. J A Gogtay, Medical Director, Cipla said, “The success of P2P in Uttar Pradesh, Haryana and Rajasthan has encouraged us to extend this program to Madhya Pradesh as well. Cipla has always been committed towards providing quality affordable medicines and this program provides us the platform to extend it to small town and rural India. Today a patient in Orcha, Mandu, Dhar, Datia or any such smaller location has access to the right asthma treatment as compared to a patient based in Mumbai or Delhi or even in developed countries with medication that is affordable to most people. ”
P2P is a unique certificate program specifically designed in Hindi and it comprises of interactive lectures by eminent chest physicians and short easy-to-follow, user-friendly sessions. The doctors participating in the program also receive diagnostic tools and relevant patient educational materials which further supports them in their practice. Trained under P2P, the primary healthcare doctors are now able to extend the currently recommended therapy for asthma treatment to the masses. The most effective asthma treatment – inhalation therapy is available in India at a price as low as Rs 4 to Rs 6 per day. The diagnosed asthma patients can thereby benefit tremendously from the affordability and availability of these inhaled drugs to keep their asthma under control and lead a complete active life. Further, to ensure that patients take their treatment regularly, the primary healthcare doctors trained under P2P are able to provide demonstration of inhaler devices and counsel the patient and his family to remove the myths associated with asthma and inhalation therapy.
Commenting on the launch of P2P, Dr. Harihar Trivedi, Ret.Prof.of Medicine, Gandhi Medical College, Bhopal said, “We are delighted about P2P being launched in Madhya Pradesh. We realize that doctors across Uttar Pradesh, Rajasthan and Haryana have benefitted from P2P in terms of knowledge upgradation and winning patient trust.
Speaking about the launch of P2P, Dr. Rajesh Bhagchandani, Instructor in Critical Care (Apex Hospital) said, “Now, doctors from M. P would also be empowered to take up the responsibility to provide best asthma treatment to patients and provide relief to several suffering needlessly with the condition.”
Asthma is a chronic respiratory disorder of the lungs in which there is inflammation (swelling) of the airways in our lungs. Due to this inflammation, the airways are narrowed and the lung becomes vulnerable to various allergens which act as triggers for an asthma attack. Dust, cold, pollen, furry pets, and viruses, smoking and air pollutants, and even emotional agitation act as triggers for an asthma attack. When a person comes in contact with a trigger, the inflamed airways are irritated leading to tightening of the muscles and excess mucus production which further constricts the passages, thereby inhibiting normal breathing and this at times could even turn fatal.
The usual manifestations of asthma are repeated episodes of chest tightness, difficulty in breathing and cough. In children asthma often manifests through a single symptom like cough which is more severe at night or early in the morning and remains persistent despite intake of various cough syrups and medications. Asthma symptoms vary from person to person and it is important to watch them carefully for a correct diagnosis by the doctor.
Although asthma is not curable, it is possible to gain complete control over it and lead a normal active life. There are several therapies and forms of treatment for asthma available in the market. However, it has now been accepted globally that the best and safest way to take asthma medication is by inhalation as it reaches your lungs directly and starts acting immediately. But if you are on tablet or syrup the medication takes time to act as the medicine has to pass from the stomach to the blood and finally to the lungs. This could also result in several side effects. It is to be noted that in inhalation therapy, the dosage needed is up to 50 times lesser than syrups or tablets and far more effective.
For more information or story ideas on asthma, please log in to www.breathefree.com/media
Cipla laid foundations for the Indian pharma industry way back in 1935. At a time when the British ruled India and medicines were neither readily available nor affordable, Dr. K. A. Hamied founded Cipla towards making the country self-reliant in healthcare. He built Cipla with a promise “Never again will India be starved of essential drugs.”
Over the years Cipla has grown to be one of the most respected names in pharmaceuticals not just in India but worldwide. It’s state- of -the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 40 manufacturing units across the country, Cipla manufactures over 1200 products in various categories and has a presence in crop care and veterinary too.
With a turnover of over 5000 crores, Cipla today serves doctors and patients in over 176 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its innovative drugs and devices.